We further aimed to explore the molecular mechanism through which PPA promotes hepatic lipolysis and fatty acid oxidation, specifically by investigating the potential involvement of the GPR43–Ca2+–CaMKII–ATGL signalling cascade, and to assess the therapeutic potential of PPA supplementation in the progression of MASLD. The gene discussed is FFAR2; the disease is metabolic dysfunction-associated steatotic liver disease.